Physician perceptions of enhanced community pharmacist care in cholesterol management: A survey of physicians contacted during the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP)

Canadian Pharmaceutical Journal

Volumn 138, Issue 4, 2005, Pages 33-39

  Simpson, Scot H ^a   Johnson, Jeffrey A ^a   Farris, Karen B ^b   Lau, Tim T Y ^c   Majumdar, Sumit R ^a   Cave, Andrew ^a   Tsuyuki, Ross T ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HEALTH SURVEY; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; PATIENT CARE; PERCEPTION; PHARMACIST; PHARMACY; PHYSICIAN ATTITUDE; REVIEW;

EID: 26044466814     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279: 1615-22.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial. Lancet 2002;360:7-22.
8. Fodor JG, Frohlich JJ, Genest JJG, McPherson PR. Recommendations for the management and treatment of dyslipidemia. CMAJ 2000; 162:1441-7.
9. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by British Diabetic Association. Joint British recommendations on prevention of CHD in clinical practice. Heart 1998;80(suppl 2):S21-9.
10. The Clinical Quality Improvement Network Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol 1995;76:570-3.
11. Olson KL, Bungard TJ, Tsuyuki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy 2001;21:807-17.
12. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996;75:334-42.
13. Bramlet DA, King H, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. Am J Cardiol 1997;80(suppl):39H-44H.
14. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238-44.
15. Giles WH, Anda RF, Jones DH, Serdula MK, Merritt RK, DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians: progress and missed opportunities. JAMA 1993;269:1133-8.
16. Hutchison BG, Abelson J, Woodward CA, Norman G. Preventive care and barriers to effective prevention: how do family physicians see it? Can Fam Physician 1996;42:1693-1700.
17. Elnicki DM, Morris DK, Shockcor WT. Patient-perceived barriers to preventive health care among indigent, rural Appalachian patients. Arch Intern Med 1995;155:421-4.
18. Tsuyuki RT, Johnson JA, Teo KK, et al. Study of cardiovascular risk intervention by pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother 1999;33:910-9.
19. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
20. Chen TF, Crampton M, Krass I, Benrimoj SI. Collaboration between community pharmacists and GPs in innovative clinical services - a conceptual model. J Soc Admin Pharm 1999;16:134-44.
21. Chen TF, Crampton M, Krass I, Benrimoj SI. Collaboration between community pharmacists and GPs - impact on interprofessional communication. J Soc Admin Pharm 2001;18:83-90.
22. Adams AS, Soumerai SB, Lomas J, Ross-Degnan D. Evidence of self-report bias in assessing adherence to guidelines. Int J Qual Health Care 1999;11:187-92.
23. Pious S. The psychology of judgement and decision making. New York: McGraw-Hill, Inc.; 1993:191-204.
24. Bradshaw SJ, Doucette WR. Community pharmacists as patient advocates: physician attitudes. J Am Pharm Assoc 1998;38:598-602.
25. Bailie GR, Romeo B. New York state primary care physicians' attitudes to community pharmacists' clinical services. Arch Intern Med 1996;156:1437-41.
26. Johnson RE, Freeborn DK, Azevedo DJ. Physicians' attitudes toward an expanded role for pharmacists in an HMO. Group Health J 1984;5(2):14-21.
27. Ritchey FJ, Raney MR. Effect of exposure on physicians' opinions of expanded clinical pharmacy services. Am J Hosp Pharm 1981;38:1459-63.
28. Commission on the Future of Health Care in Canada, Romanow RJ. Building on values: the future of health care in Canada. Saskatoon, SK: Commission on the Future of Health Care in Canada; 2002.